DRUG
Provera 10 mg.
One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation
Status
Completed
Phase
Phase 3
Enrollment
318
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
The purpose of this study is to determine whether Medroxyprogesterone Acetate (MPA) administration in follicular phase prevents premature luteinization with equal efficiency as GnRH antagonists and otains similar clinical results in oocyte donation.
Full detailed description
Within the new guidelines for stimulation, the use of oral progesterone in follicular phase allows GnRH analogue administration, resulting in greater comfort for patients as well as a reduction in cost. Obtained results are similar to those from conventional protocols in terms of: early luteinization, number of oocytes, embryos number and rate of implantation and gestation or appearance of congenital malformations. Another advantage is the lower incidence of OHSS (Ovarian Hyperstimulation Syndrome). From a scientific point of view, it would allow a better understanding of folliculogenesis, of progesterone mechanism of action on blocking LH secretion and its effect on ovarian and later embryonic level. From a clinical point of view, it would simplify COS (Controlled Ovarian Stimulation) by reducing the number of medication administered subcutaneously and their possible side effects on both systemic and local levels. It would be of special interest in 2 groups of patients, for example, oocyte donors and patients undergoing preservation of fertility. To date, there is a lack of studies along these lines.
Interventions
Treatment arms and agents.
DRUG
Ganirelix (GnRH antagonist)
One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
Timeline
From registration to results.
First posted
Oct 4, 2017
Study start
Oct 20, 2017
Primary completion
Jun 25, 2019
Study completion
Jun 25, 2019
Results posted
Not reported
Registry updated
Aug 25, 2021
Outcomes
What the study measures.
Primary outcomes
Compare number of oocytes using GnRH antagonist versus PMA.
Time frame · 36 hours: from triggering until Oocyte retrieval
Compare oocytes in COS cycles between two groups: using GnRH antagonist versus PMA for avoiding premature luteinization.
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 35 Years
- Sex
- FEMALE
- Healthy volunteers
- Yes
Inclusion Criteria: * Age between 18-35 years (both included) * Regular Menses (between 25-35 days) * Absence of physical and psychic pathologies at the time of oocyte donation * BMI: 18-28 kg(m2 at the time of oocyte donation. * Other criteria to comply with: i. With no relevant personal or family medical history ii. Signing of Informed Consent iii. From a medical point of view: 1. Healthy ovaries and uterus, with no organic pathology 2. Ovaries without polycystic aspect 3. Antral Follicle Count \> 12 in the sum of both ovaries 4. Normal Karyotype 5. Negative results in infectious illness screening (Hepatitis B Virus; Hepatitis C Virus, VIH Virus Syphilis) 6. Results within range of general analysis of hemogram, hemostasia y biochemistry. Exclusion Criteria: * Any systemic or metabolic disorder which contraindicate the use of Gonadotrophines * Medical background of Trombophlebitis or thromboembolic phenomena or Arterial Hypertension * Severe hepatic insufficiency, cardiovascular illness * Suspicion or evidence of malignity of mamarian glands or other hormone dependant genital organs * Known infection of Hepatitis B Virus; Hepatitis C Virus or VIH Virus * Known hypersensitivity to PMA or its excipients * Any reason or cause which excluede from the oocyte donation program * Participation in another clinical trial in the two months prior to the inclusion on this study
Study locations
1 registered sites.
Spain. Showing up to 24 locations stored in the fast local snapshot.
IVI Valencia
Valencia, Spain
Related trials
More studies on Ganirelix.
NCT IDStudyPhase / statusEnrollmentUpdated
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women
University of Delaware · Estrogen · Premenopause
Phase 4
Recruiting
30
2026-07
Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?
ART Fertility Clinics LLC · Healthy
Not applicable
Not yet recruiting
20
2026-05
INTEnsity of ovariaN Stimulation and Embryo Quality
Fundación Santiago Dexeus Font · Infertility
Phase 4
Completed
110
2026-04
Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.
Instituto Bernabeu · IVF
Phase 4
Completed
150
2026-03
IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols
Hanoi Medical University · Infertility (IVF Patients) · Embryo Morphokinetics
Not applicable
Recruiting
148
2026-02
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
University Hospital, Ghent · Ovarian Stimulation · Quality of Life
Phase 4
Recruiting
60
2025-12
DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT
Tam Anh TP. Ho Chi Minh General Hospital · Diminished Ovarian Reserve
Not applicable
Recruiting
730
2025-12
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.